Limits...
Antibiotic-free selection in biotherapeutics: now and forever.

Mignon C, Sodoyer R, Werle B - Pathogens (2015)

Bottom Line: The continuously improving sophistication of molecular engineering techniques gives access to novel classes of bio-therapeutics and new challenges for their production in full respect of the strengthening regulations.Among these biologic agents are DNA based vaccines or gene therapy products and to a lesser extent genetically engineered live vaccines or delivery vehicles.The use of antibiotic-based selection, frequently associated with genetic manipulation of microorganism is currently undergoing a profound metamorphosis with the implementation and diversification of alternative selection means.

View Article: PubMed Central - PubMed

Affiliation: Technology Research Institute Bioaster, 317 avenue Jean-Jaurés, 69007 Lyon, France. Charlotte.mignon@bioaster.org.

ABSTRACT
The continuously improving sophistication of molecular engineering techniques gives access to novel classes of bio-therapeutics and new challenges for their production in full respect of the strengthening regulations. Among these biologic agents are DNA based vaccines or gene therapy products and to a lesser extent genetically engineered live vaccines or delivery vehicles. The use of antibiotic-based selection, frequently associated with genetic manipulation of microorganism is currently undergoing a profound metamorphosis with the implementation and diversification of alternative selection means. This short review will present examples of alternatives to antibiotic selection and their context of application to highlight their ineluctable invasion of the bio-therapeutic world.

No MeSH data available.


Related in: MedlinePlus

Minicircle production. The producer plasmid is selected using an antibiotic resistance gene. Cleavage and recombination leads to the formation of circular plasmid backbones and minicircles. Minicircles do not contain any antibiotic resistance gene. Strategies of in vivo degradation of plasmid backbone are developed to facilitate minicircle purification.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493468&req=5

pathogens-04-00157-f006: Minicircle production. The producer plasmid is selected using an antibiotic resistance gene. Cleavage and recombination leads to the formation of circular plasmid backbones and minicircles. Minicircles do not contain any antibiotic resistance gene. Strategies of in vivo degradation of plasmid backbone are developed to facilitate minicircle purification.


Antibiotic-free selection in biotherapeutics: now and forever.

Mignon C, Sodoyer R, Werle B - Pathogens (2015)

Minicircle production. The producer plasmid is selected using an antibiotic resistance gene. Cleavage and recombination leads to the formation of circular plasmid backbones and minicircles. Minicircles do not contain any antibiotic resistance gene. Strategies of in vivo degradation of plasmid backbone are developed to facilitate minicircle purification.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493468&req=5

pathogens-04-00157-f006: Minicircle production. The producer plasmid is selected using an antibiotic resistance gene. Cleavage and recombination leads to the formation of circular plasmid backbones and minicircles. Minicircles do not contain any antibiotic resistance gene. Strategies of in vivo degradation of plasmid backbone are developed to facilitate minicircle purification.
Bottom Line: The continuously improving sophistication of molecular engineering techniques gives access to novel classes of bio-therapeutics and new challenges for their production in full respect of the strengthening regulations.Among these biologic agents are DNA based vaccines or gene therapy products and to a lesser extent genetically engineered live vaccines or delivery vehicles.The use of antibiotic-based selection, frequently associated with genetic manipulation of microorganism is currently undergoing a profound metamorphosis with the implementation and diversification of alternative selection means.

View Article: PubMed Central - PubMed

Affiliation: Technology Research Institute Bioaster, 317 avenue Jean-Jaurés, 69007 Lyon, France. Charlotte.mignon@bioaster.org.

ABSTRACT
The continuously improving sophistication of molecular engineering techniques gives access to novel classes of bio-therapeutics and new challenges for their production in full respect of the strengthening regulations. Among these biologic agents are DNA based vaccines or gene therapy products and to a lesser extent genetically engineered live vaccines or delivery vehicles. The use of antibiotic-based selection, frequently associated with genetic manipulation of microorganism is currently undergoing a profound metamorphosis with the implementation and diversification of alternative selection means. This short review will present examples of alternatives to antibiotic selection and their context of application to highlight their ineluctable invasion of the bio-therapeutic world.

No MeSH data available.


Related in: MedlinePlus